Journal
ANTICANCER RESEARCH
Volume 39, Issue 3, Pages 1455-1461Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13262
Keywords
Glasgow prognostic score; anti-PD1; non-small cell lung cancer; immunotherapy; biomarker
Categories
Ask authors/readers for more resources
Background/Aim: No definitive biomarker exists for predicting treatment efficacy or response to therapy with antibody to programmed cell death-1 (PD1) for patients with advanced non-small cell lung cancer (NSCLC). Hence, we investigated whether the Glasgow prognostic score (GPS) predicted anti-PD1 treatment response for advanced NSCLC. Patients and Methods: This study retrospectively identified 47 patients with NSCLC treated with anti-PD1 and assessed the prognostic value of the GPS. The GPS was calculated using C-reactive protein and albumin concentrations 1 month after starting anti-PD1 treatment. Kaplan-Meier method and Cox proportional hazard models were used to examine differences in progression-free (PFS) and overall (OS) survival, and clinical response. Results: The post-treatment GPS independently predicted anti-PD1 treatment efficacy, as a good post-treatment GPS (GPS 0-1) was significantly associated with improved PFS. Intra-treatment GPS change was associated with clinical response. Conclusion: The post-treatment GPS independently predicted efficacy of anti-PD1 treatment for NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available